JP Morgan Chase
FDMT icon

JP Morgan Chase’s 4D Molecular Therapeutics FDMT Stock Holding History

JP Morgan Chase’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,600
Closed -$529K – 7477
2024
Q1 		$529K Sell
16,600
-40,900
-71% -$1.04M ﹤0.01% 4757
2023
Q4 		$1.16M Buy
+57,500
New +$757K ﹤0.01% 4234

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

JP Morgan Chase's FDMT Position: Q2 2026 in Review

JP Morgan Chase reduced its 4D Molecular Therapeutics (FDMT) stake by 3.3% in Q2 2026, selling an estimated $132K and leaving 402,137 shares worth $5.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3417.

JP Morgan Chase first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $12.8M in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • JP Morgan Chase held 402,137 shares of 4D Molecular Therapeutics worth $5.18M as of Q2 2026.
  • JP Morgan Chase sold 13,518 4D Molecular Therapeutics shares in Q2 2026, an estimated $132K.
  • 4D Molecular Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3417 holding.
  • JP Morgan Chase first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • JP Morgan Chase's 4D Molecular Therapeutics position peaked at $12.8M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.